Class II HLA Genotype Association With First-Phase Insulin Response Is Explained by Islet Autoantibodies | Zendy

Maarit Koskinen | Zendy; Johanna Lempainen | Zendy; Eliisa Löyttyniemi | Zendy; Olli Helminen | Zendy; Anne Hekkala | Zendy; Taina Härkönen | Zendy; Minna Kiviniemi | Zendy; Olli Simell | Zendy; Mikael Knip | Zendy; Jorma Ilonen | Zendy; Jorma Toppari | Zendy; Riitta Veijola | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Class II HLA Genotype Association With First-Phase Insulin Response Is Explained by Islet Autoantibodies

Author(s) -

Maarit Koskinen,

Johanna Lempainen,

Eliisa Löyttyniemi,

Olli Helminen,

Anne Hekkala,

Taina Härkönen,

Minna Kiviniemi,

Olli Simell,

Mikael Knip,

Jorma Ilonen,

Jorma Toppari,

Riitta Veijola

Publication year - 2017

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2017-02040

Subject(s) - autoantibody , islet , genotype , medicine , human leukocyte antigen , hla dq , endocrinology , autoimmunity , type 1 diabetes , diabetes mellitus , immunology , antigen , biology , disease , antibody , haplotype , genetics , gene

A declining first-phase insulin response (FPIR) is characteristic of the disease process leading to clinical type 1 diabetes. It is not known whether reduced FPIR depends on class II human leukocyte antigen (HLA) genotype, islet autoimmunity, or both.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research